| ［1］ |
Choon SE, Navarini AA, Pinter A. Clinical course and characteristics of generalized pustular psoriasis［J］. Am J Clin Dermatol, 2022,23（Suppl 1）:21⁃29. doi: 10.1007/s40257⁃021⁃00654⁃z.
|
| ［2］ |
Zhou J, Luo Q, Cheng Y, et al. An update on genetic basis of generalized pustular psoriasis （review）［J］. Int J Mol Med, 2021,47（6）:118 ［pii］. doi: 10.3892/ijmm.2021.4951.
|
| ［3］ |
Mrowietz U, Domm S. Systemic steroids in the treatment of psoriasis: what is fact, what is fiction?［J］. J Eur Acad Dermatol Venereol, 2013,27（8）:1022⁃1025. doi: 10.1111/j.1468⁃3083. 2012.04656.x.
|
| ［4］ |
Blair HA. Spesolimab: first approval［J］. Drugs, 2022,82（17）:1681⁃1686. doi: 10.1007/s40265⁃022⁃01801⁃4.
|
| ［5］ |
Choon SE, Lebwohl MG, Marrakchi S, et al. Study protocol of the global Effisayil 1 phaseⅡ, multicentre, randomised, double⁃blind, placebo⁃controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare［J］. BMJ Open, 2021,11（3）:e043666. doi: 10.1136/bmjopen⁃2020⁃043666.
|
| ［6］ |
Navarini AA, Prinz JC, Morita A, et al. Spesolimab improves patient⁃reported outcomes in patients with generalized pustular psoriasis: results from the Effisayil 1 study［J］. J Eur Acad Dermatol Venereol, 2023,37（4）:730⁃736. doi: 10.1111/jdv. 18820.
|
| ［7］ |
Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis［J］. N Engl J Med, 2021,385（26）:2431⁃2440. doi: 10.1056/NEJMoa2111563.
|
| ［8］ |
Mai SZ, Li CJ, Xie XY, et al. Increased serum IL⁃36α and IL⁃36γ levels in patients with systemic lupus erythematosus: association with disease activity and arthritis［J］. Int Immunopharmacol, 2018,58:103⁃108. doi: 10.1016/j.intimp.2018.03.011.
|
